Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
Alimentary Pharmacology & Therapeutics|February 22, 2002
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studiesG N J Tytgat, L Van Nueten, I Van De Velde, et al.
Diseases of the Colon and Rectum|December 1, 1995
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporinP R Fleshner, F Michelassi, M Rubin, et al.
Journal of Clinical Gastroenterology|August 1, 1990
ACTH-induced adrenal hemorrhage: a complication of therapy masquerading as an acute abdomenA A Kornbluth, P Salomon, D B Sachar, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|December 15, 2007
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trialS B Hanauer, W J Sandborn, C Dallaire, et al.
The American Journal of Gastroenterology|November 30, 2000
Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel diseaseH S Te, T D Schiano, S F Kuan, et al.
Annals of Surgery|September 6, 2000
Side-to-side isoperistaltic strictureplasty in extensive Crohn's disease: a prospective longitudinal studyF Michelassi, R D Hurst, M Melis, et al.
Alimentary Pharmacology & Therapeutics|September 1, 2005
Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurineM P Sparrow, S A Hande, S Friedman, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 7, 2016
Quiet transcranial magnetic stimulation: Status and future directionsAngel V Peterchev, David L K Murphy, Stefan M Goetz
Gastroenterology|May 1, 1993
Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study GroupJ W Singleton, S B Hanauer, G L Gitnick, et al.
Alimentary Pharmacology & Therapeutics|June 5, 2013
Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's diseaseW J Sandborn, D E Elliott, J Weinstock, et al.
Pageof 16